A phase III, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has progressed after prior VEGFR Tyrosine Kinase Inhibitor Therapy

What is the purpose of this trial?

The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.


Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Exelexis, Inc.
Dates:
Last Updated:
Study HIC#: 1311013092